Oasmia will issue to each investor in its proposed offering of American Depositary Shares, or ADSs, one warrant to purchase such ADSs for each two ADSs sold in the offering. The warrants will be exercisable immediately at an exercise price of 125% of the offering price of the ADSs and will expire four (4) years from the date of issuance. At full dilution, the transaction will bring in approximately the same size of Company’s initial offering size. The ADSs and warrants will be separately issued, but will be issued and sold in equal proportions.
The Company hereby announces that Joseph Gunnar & Co., LLC, and Rodman & Renshaw, a unit of H.C. Wainwright & Co., LLC. will act as joint book-running manager(s) for the proposed offering,. The number of American Depositary Shares representing Ordinary Shares to be offered and the price of the American Depositary Shares to be sold in the offering, have not yet been determined.
The offering of these securities will be made only by means of a prospectus. Copies of the preliminary prospectus relating to the offering may be obtained from Vallongatan 1, Telephone: +46 18 50 54 40, Facsimile: +46 18 51 08 73 or by Emailing: info@oasmia.com. In addition, the registration statement, including the prospectus, is available to the public at www.sec.gov or www.vivesto.com.
About Oasmia Pharmaceutical AB
Oasmia Pharmaceutical AB develops new generations of drugs in the field of human and veterinary oncology. The company’s product development aims to create and manufacture novel nanoparticle formulations and drug-delivery systems based on well-established cytostatics which, in comparison with current alternatives show improved properties, reduced side-effects, and expanded applications. The company’s product development is based on its proprietary in-house research and company patents. Oasmia is listed on NASDAQ Stockholm (OASM) and the Frankfurt Stock Exchange (OMAX, ISIN SE0000722365).